Magenta Therapeutics, Inc.
MGTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $396 | $193 | $1,163 | $6,235 |
| % Growth | 105.2% | -83.4% | -81.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 0% | 0% | 0% | 0% |
| R&D Expenses | $32,489 | $26,251 | $27,003 | $67,011 |
| G&A Expenses | $8,195 | $8,869 | $7,337 | $4,821 |
| SG&A Expenses | $8,195 | $8,869 | $7,337 | $4,821 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $40,684 | $35,120 | $34,340 | $71,832 |
| Operating Income | -$40,288 | -$34,927 | -$33,177 | -$82,606 |
| % Margin | -10,173.7% | -18,096.9% | -2,852.7% | -1,324.9% |
| Other Income/Exp. Net | $3,523 | $3,298 | $3,666 | $44,854 |
| Pre-Tax Income | -$36,765 | -$31,629 | -$29,511 | -$37,752 |
| Tax Expense | $0 | $0 | $0 | $8,969 |
| Net Income | -$36,765 | -$31,629 | -$29,511 | -$32,337 |
| % Margin | -9,284.1% | -16,388.1% | -2,537.5% | -518.6% |
| EPS | -9.41 | -8.1 | -7.55 | 13.02 |
| % Growth | -16.2% | -7.3% | -158% | – |
| EPS Diluted | -9.41 | -8.1 | -7.55 | 13.02 |
| Weighted Avg Shares Out | 3,907 | 3,907 | 3,907 | 3,907 |
| Weighted Avg Shares Out Dil | 3,907 | 3,907 | 3,907 | 3,907 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,658 | $3,403 | $3,791 | $9,287 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $99 | $0 | $0 | -$4,217 |
| EBITDA | -$36,666 | -$34,927 | -$33,177 | -$35,960 |
| % Margin | -9,259.1% | -18,096.9% | -2,852.7% | -576.8% |